Crossject (ALCJ) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.640x

Based on the latest financial reports, Crossject (ALCJ) has a cash flow conversion efficiency ratio of 0.640x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.12 Million ≈ $-3.64 Million USD) by net assets (€-4.87 Million ≈ $-5.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Crossject market cap and net worth for the company's overall valuation and market capitalisation.

Crossject - Cash Flow Conversion Efficiency Trend (2012–2025)

This chart illustrates how Crossject's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Crossject Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Crossject ranked by their cash flow conversion efficiency. See ALCJ operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.

Company	Cash Flow Conversion Efficiency
Amata Summit Growth Freehold and Leasehold Real Estate Investment Trust BK:AMATAR	0.017x
Munsin Garment TWO:2916	-0.053x
Many Peaks Minerals Ltd AU:MPK	-0.020x
Tonymoly Co Ltd KO:214420	0.016x
Greenheart Gold Inc. V:GHRT	-0.089x
Bioton S.A. WAR:BIO	0.004x
Cullman Bancorp Inc. NASDAQ:CULL	0.018x
Bflysoft Co. Ltd. KQ:148780	-0.032x

Annual Cash Flow Conversion Efficiency for Crossject (2012–2025)

The table below shows the annual cash flow conversion efficiency of Crossject from 2012 to 2025. View latest Crossject stock price today for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	€-4.87 Million ≈ $-5.69 Million	€-6.35 Million ≈ $-7.42 Million	1.304x	-56.19%
2024-12-31	€-2.67 Million ≈ $-3.13 Million	€-7.96 Million ≈ $-9.30 Million	2.977x	+152.94%
2023-12-31	€-5.27 Million ≈ $-6.16 Million	€-6.20 Million ≈ $-7.25 Million	1.177x	+162.23%
2022-12-31	€2.69 Million ≈ $3.14 Million	€-5.08 Million ≈ $-5.94 Million	-1.891x	-270.39%
2021-12-31	€-5.48 Million ≈ $-6.41 Million	€-6.08 Million ≈ $-7.11 Million	1.110x	-77.03%
2020-12-31	€-1.13 Million ≈ $-1.32 Million	€-5.46 Million ≈ $-6.39 Million	4.833x	+364.36%
2019-12-31	€3.01 Million ≈ $3.52 Million	€-5.51 Million ≈ $-6.44 Million	-1.828x	+62.27%
2018-12-31	€1.65 Million ≈ $1.93 Million	€-8.02 Million ≈ $-9.37 Million	-4.845x	-492.85%
2017-12-31	€6.09 Million ≈ $7.11 Million	€-4.97 Million ≈ $-5.82 Million	-0.817x	-16.62%
2016-12-31	€6.28 Million ≈ $7.35 Million	€-4.40 Million ≈ $-5.15 Million	-0.701x	-28.56%
2015-12-31	€8.80 Million ≈ $10.29 Million	€-4.80 Million ≈ $-5.61 Million	-0.545x	-149.64%
2014-12-31	€14.48 Million ≈ $16.93 Million	€-3.16 Million ≈ $-3.70 Million	-0.218x	+78.53%
2013-12-31	€947.65K ≈ $1.11 Million	€-964.00K ≈ $-1.13 Million	-1.017x	-440.48%
2012-12-31	€-1.90 Million ≈ $-2.23 Million	€-569.06K ≈ $-665.29K	0.299x	--

About Crossject

PA:ALCJ France Medical Instruments & Supplies

Market Cap

$82.54 Million

€70.61 Million EUR

Market Cap Rank

#20031 Global

#304 in France

Share Price

€1.33

Change (1 day)

+0.61%

52-Week Range

€1.31 - €2.69

All Time High

€10.40